$RIGL
RIGEL PHARMACEUTICALS INC

2020 Q3 Form 10-Q Financial Statement

#000155837020012838 Filed on November 05, 2020

View on sec.gov

Income Statement

Concept 2020 Q3 2019 Q3 2019 Q2
Revenue $18.39M $20.86M $10.41M
YoY Change -11.83% 328.28% 481.4%
Cost Of Revenue $140.0K $310.0K $311.0K
YoY Change -54.84% 342.86% 936.67%
Gross Profit $16.15M $11.41M $9.862M
YoY Change 41.58% 137.63% 460.34%
Gross Profit Margin 87.82% 54.69% 94.76%
Selling, General & Admin $17.43M $18.12M $18.21M
YoY Change -3.81% 0.28% 6.67%
% of Gross Profit 107.93% 158.87% 184.64%
Research & Development $14.60M $14.46M $13.23M
YoY Change 0.95% 30.3% 22.46%
% of Gross Profit 90.41% 126.8% 134.11%
Depreciation & Amortization $160.0K $160.0K $180.0K
YoY Change 0.0% 0.0% 12.5%
% of Gross Profit 0.99% 1.4% 1.83%
Operating Expenses $32.03M $32.58M $31.44M
YoY Change -1.7% 11.7% 12.79%
Operating Profit -$13.78M -$12.04M -$21.34M
YoY Change 14.49% -50.61% -18.27%
Interest Expense $429.0K $8.000K $730.0K
YoY Change 5262.5% -98.67% 32.73%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$14.17M -$11.49M -$20.61M
YoY Change 23.36% -51.66% -19.37%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$14.17M -$11.49M -$20.61M
YoY Change 23.36% -51.66% -19.37%
Net Earnings / Revenue -77.08% -55.09% -198.04%
Basic Earnings Per Share -$0.08
Diluted Earnings Per Share -$0.08 -$68.55K -$123.3K
COMMON SHARES
Basic Shares Outstanding 168.9M 167.6M 167.2M
Diluted Shares Outstanding 168.9M 167.6M 167.2M

Balance Sheet

Concept 2020 Q3 2019 Q3 2019 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $72.80M $107.5M $112.4M
YoY Change -32.28% -7.01% -16.74%
Cash & Equivalents $36.57M $39.09M $44.23M
Short-Term Investments $36.20M $68.40M $68.10M
Other Short-Term Assets $10.40M $5.800M $4.000M
YoY Change 79.31% 262.5% 100.0%
Inventory $2.050M $1.200M $1.200M
Prepaid Expenses
Receivables $14.63M $11.60M $6.900M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $99.85M $126.0M $124.5M
YoY Change -20.76% 4.13% -10.5%
LONG-TERM ASSETS
Property, Plant & Equipment $2.517M $29.40M $30.90M
YoY Change -91.44% 1860.0% 1960.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $820.0K $700.0K $700.0K
YoY Change 17.14% 0.0% 0.0%
Total Long-Term Assets $23.21M $30.10M $31.70M
YoY Change -22.89% 1268.18% 1409.52%
TOTAL ASSETS
Total Short-Term Assets $99.85M $126.0M $124.5M
Total Long-Term Assets $23.21M $30.10M $31.70M
Total Assets $123.1M $156.1M $156.2M
YoY Change -21.17% 26.7% 10.62%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.283M $2.700M $3.800M
YoY Change -15.44% 3.85% 15.15%
Accrued Expenses $28.80M $26.80M $23.20M
YoY Change 7.46% 56.73% 65.71%
Deferred Revenue $3.069M
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $34.19M $31.00M $28.40M
YoY Change 10.3% 57.36% 63.22%
LONG-TERM LIABILITIES
Long-Term Debt $19.80M $9.800M $0.00
YoY Change 102.04%
Other Long-Term Liabilities $5.000M $46.40M $49.50M
YoY Change -89.22% 16400.0%
Total Long-Term Liabilities $5.000M $56.20M $49.50M
YoY Change -91.1% 16400.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $34.19M $31.00M $28.40M
Total Long-Term Liabilities $5.000M $56.20M $49.50M
Total Liabilities $39.19M $87.20M $77.90M
YoY Change -55.06% 342.64% 340.11%
SHAREHOLDERS EQUITY
Retained Earnings -$1.287B
YoY Change
Common Stock $1.338B
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $50.96M $68.91M $78.29M
YoY Change
Total Liabilities & Shareholders Equity $123.1M $156.1M $156.2M
YoY Change -21.17% 26.7% 10.62%

Cashflow Statement

Concept 2020 Q3 2019 Q3 2019 Q2
OPERATING ACTIVITIES
Net Income -$14.17M -$11.49M -$20.61M
YoY Change 23.36% -51.66% -19.37%
Depreciation, Depletion And Amortization $160.0K $160.0K $180.0K
YoY Change 0.0% 0.0% 12.5%
Cash From Operating Activities -$19.48M -$14.64M -$16.65M
YoY Change 33.06% -27.09% -38.33%
INVESTING ACTIVITIES
Capital Expenditures -$200.0K -$350.0K -$110.0K
YoY Change -42.86% 118.75% -83.82%
Acquisitions
YoY Change
Other Investing Activities $19.72M $50.00K -$14.55M
YoY Change 39340.0% -99.69% -6.25%
Cash From Investing Activities $19.53M -$290.0K -$14.68M
YoY Change -6834.48% -101.83% -9.38%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 50.00K 9.800M 850.0K
YoY Change -99.49% 1431.25% -98.75%
NET CHANGE
Cash From Operating Activities -19.48M -14.64M -16.65M
Cash From Investing Activities 19.53M -290.0K -14.68M
Cash From Financing Activities 50.00K 9.800M 850.0K
Net Change In Cash 100.0K -5.130M -30.48M
YoY Change -101.95% 42.9% -222.16%
FREE CASH FLOW
Cash From Operating Activities -$19.48M -$14.64M -$16.65M
Capital Expenditures -$200.0K -$350.0K -$110.0K
Free Cash Flow -$19.28M -$14.29M -$16.54M
YoY Change 34.92% -28.26% -37.16%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2020Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
0
us-gaap Other Than Temporary Impairment Loss Debt Securities Available For Sale Recognized In Earnings
OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings
0
CY2020Q3 rigl Net Sublease Income Expense
NetSubleaseIncomeExpense
rigl Net Sublease Income Expense
NetSubleaseIncomeExpense
dei Entity Registrant Name
EntityRegistrantName
RIGEL PHARMACEUTICALS INC
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
22521000
CY2020Q3 us-gaap Short Term Investments
ShortTermInvestments
36245000
CY2019Q4 us-gaap Short Term Investments
ShortTermInvestments
75557000
CY2020Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
14631000
CY2019Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
10111000
CY2020Q3 us-gaap Inventory Net
InventoryNet
2050000
CY2019Q4 us-gaap Inventory Net
InventoryNet
1354000
CY2020Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
10355000
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001034842
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Amendment Flag
AmendmentFlag
false
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2020-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
0-29889
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
94-3248524
dei Entity Address Address Line1
EntityAddressAddressLine1
1180 Veterans Blvd.
dei Entity Address City Or Town
EntityAddressCityOrTown
South San Francisco
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94080
dei City Area Code
CityAreaCode
650
dei Local Phone Number
LocalPhoneNumber
624-1100
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
dei Trading Symbol
TradingSymbol
RIGL
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2020Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
168981434
CY2020Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
36567000
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
9462000
CY2020Q3 us-gaap Assets Current
AssetsCurrent
99848000
CY2019Q4 us-gaap Assets Current
AssetsCurrent
119005000
CY2020Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2517000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2159000
CY2020Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
19873000
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
25709000
CY2020Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
820000
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
696000
CY2020Q3 us-gaap Assets
Assets
123058000
CY2019Q4 us-gaap Assets
Assets
147569000
CY2020Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
2283000
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4152000
CY2020Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
8173000
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
8819000
CY2020Q3 rigl Accrued Research And Development Liability Current
AccruedResearchAndDevelopmentLiabilityCurrent
3296000
CY2019Q4 rigl Accrued Research And Development Liability Current
AccruedResearchAndDevelopmentLiabilityCurrent
5960000
CY2020Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
9037000
CY2019Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
6721000
CY2020Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
8334000
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
7272000
CY2020Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
3069000
CY2019Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
25288000
CY2020Q3 us-gaap Liabilities Current
LiabilitiesCurrent
34192000
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
58212000
CY2020Q3 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
146000
CY2019Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
1404000
CY2020Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
12929000
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
19230000
CY2020Q3 us-gaap Long Term Loans Payable
LongTermLoansPayable
19836000
CY2019Q4 us-gaap Long Term Loans Payable
LongTermLoansPayable
9810000
CY2020Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
5000000
CY2019Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
5098000
CY2020Q3 us-gaap Common Stock Value
CommonStockValue
169000
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
168000
CY2020Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1337519000
CY2019Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1329852000
CY2020Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
2000
CY2019Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
23000
CY2020Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1286735000
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1276228000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
50955000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
53815000
CY2020Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
123058000
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
147569000
CY2020Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
18389000
CY2019Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
20857000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
90171000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
43888000
CY2020Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
140000
CY2019Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
310000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
574000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
728000
CY2020Q3 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
14600000
CY2019Q3 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
14463000
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
44963000
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
38638000
CY2020Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
17430000
CY2019Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
18121000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
54780000
us-gaap Investment Income Interest
InvestmentIncomeInterest
563000
us-gaap Investment Income Interest
InvestmentIncomeInterest
2068000
CY2020Q3 us-gaap Interest Expense
InterestExpense
429000
CY2019Q3 us-gaap Interest Expense
InterestExpense
8000
us-gaap Interest Expense
InterestExpense
924000
us-gaap Interest Expense
InterestExpense
8000
CY2020Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-14174000
CY2019Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-11490000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
56276000
CY2020Q3 us-gaap Costs And Expenses
CostsAndExpenses
32170000
CY2019Q3 us-gaap Costs And Expenses
CostsAndExpenses
32894000
us-gaap Costs And Expenses
CostsAndExpenses
100317000
us-gaap Costs And Expenses
CostsAndExpenses
95642000
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-13781000
CY2019Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-12037000
us-gaap Operating Income Loss
OperatingIncomeLoss
-10146000
us-gaap Operating Income Loss
OperatingIncomeLoss
-51754000
CY2020Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
36000
CY2019Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
555000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-10507000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-49694000
CY2020Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.08
CY2019Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.07
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.06
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.30
CY2020Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
168932000
CY2019Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
167609000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
168658000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
167326000
CY2020Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-14174000
CY2019Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-11490000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-10507000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-49694000
CY2020Q3 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-44000
CY2019Q3 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-7000
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-21000
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
60000
CY2020Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-14218000
CY2019Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-11497000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-10528000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-49634000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
53815000
CY2020Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
21243000
CY2020Q1 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
55000
CY2020Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1336000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2050000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
78499000
CY2020Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-17576000
CY2020Q2 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-32000
CY2020Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
541000
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1778000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
63210000
CY2020Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-14174000
CY2020Q3 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-44000
CY2020Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
52000
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1911000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
50955000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
109877000
CY2019Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-17598000
CY2019Q1 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
34000
CY2019Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
16000
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2986000
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
95315000
CY2019Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-20606000
CY2019Q2 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
33000
CY2019Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
856000
CY2019Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2693000
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
78291000
CY2019Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-11490000
CY2019Q3 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-7000
CY2019Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
9000
CY2019Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2108000
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
68911000
us-gaap Profit Loss
ProfitLoss
-10507000
us-gaap Profit Loss
ProfitLoss
-49694000
us-gaap Share Based Compensation
ShareBasedCompensation
5665000
us-gaap Share Based Compensation
ShareBasedCompensation
7704000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
500000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
503000
us-gaap Operating Lease Expense
OperatingLeaseExpense
5836000
us-gaap Operating Lease Expense
OperatingLeaseExpense
5181000
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
171000
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
917000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
4520000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
7475000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
235000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
195000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
893000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2000000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
124000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-40000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1869000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-3730000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-646000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-2886000
rigl Increase Decrease In Accrued Research And Development Liability
IncreaseDecreaseInAccruedResearchAndDevelopmentLiability
-2664000
rigl Increase Decrease In Accrued Research And Development Liability
IncreaseDecreaseInAccruedResearchAndDevelopmentLiability
-1132000
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
1731000
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
3207000
rigl Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-5239000
rigl Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-4793000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-23477000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
24326000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-36613000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-31861000
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
63671000
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
100501000
us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
103184000
us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
85306000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
758000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
844000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
38755000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-16039000
us-gaap Proceeds From Long Term Lines Of Credit
ProceedsFromLongTermLinesOfCredit
9975000
us-gaap Proceeds From Long Term Lines Of Credit
ProceedsFromLongTermLinesOfCredit
9789000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
1929000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
882000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
11904000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
10671000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
14046000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-37229000
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
22521000
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
76322000
CY2020Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
36567000
CY2019Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
39093000
us-gaap Interest Paid Net
InterestPaidNet
814000
us-gaap Nature Of Operations
NatureOfOperations
<table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;"><b style="font-size:10pt;font-weight:bold;">1.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;"><b style="font-size:10pt;font-weight:bold;">Nature of Operations</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We are a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. Our pioneering research focuses on signaling pathways that are critical to disease mechanisms. Our first product approved by the United States Food and Drug Administration (FDA) is TAVALISSE<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">®</sup> (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment. The product has been approved by the European Commission (EC) for the treatment of chronic ITP in adult patients who are refractory to other treatments and is marketed in Europe under the name TAVLESSE<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">® </sup>(fostamatinib). Fostamatinib is currently being studied in a Phase 3 trial for the treatment of warm autoimmune hemolytic anemia (AIHA); a NIH/NHLBI-Sponsored Phase 2 trial for the treatment of hospitalized COVID-19 patients, in collaboration with Inova<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">®</sup> Health System; and a Phase 2 trial for the treatment of COVID-19 pneumonia being conducted by Imperial College London. Additionally, we plan to study fostamatinib in a Phase 3 clinical trial for the treatment of hospitalized COVID-19 patients which is expected to launch in the fourth quarter of 2020. Other clinical trials include an ongoing Phase 1 study of R835, a proprietary molecule from its interleukin receptor associated kinase (IRAK) inhibitor program; and an ongoing Phase 1 study of R552, a proprietary molecule from its receptor-interacting protein kinase (RIP) inhibitor program. In addition, we have product candidates in clinical development with partners AstraZeneca (AZ), BerGenBio ASA (BerGenBio), and Daiichi Sankyo (Daiichi).</p>
us-gaap Basis Of Accounting
BasisOfAccounting
<table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;"><b style="font-size:10pt;font-weight:bold;">2.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;"><b style="font-size:10pt;font-weight:bold;">Basis of Presentation</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Our accompanying unaudited condensed financial statements have been prepared in accordance with U.S. generally accepted accounting principles (U.S. GAAP), for interim financial information and pursuant to the instructions to Form 10-Q and Article 10 of Regulation S-X of the Securities Act of 1933, as amended (Securities Act). Accordingly, they do not include all the information and notes required by U.S. GAAP for complete financial statements. These unaudited condensed financial statements include only normal and recurring adjustments that we believe are necessary to fairly state our financial position and the results of our operations and cash flows. Interim-period results are not necessarily indicative of results of operations or cash flows for a full-year or any subsequent interim period. The balance sheet at December 31, 2019 has been derived from audited financial statements at that date but does not include all disclosures required by U.S. GAAP for complete financial statements. Because certain disclosures required by U.S. GAAP for complete financial statements are not included herein, these interim unaudited condensed financial statements and the notes accompanying them should be read in conjunction with our audited financial statements and the notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2019.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances. Actual results could differ from these estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p>
rigl Share Based Compensation Number Of Stock Option Plans
ShareBasedCompensationNumberOfStockOptionPlans
2
CY2018Q4 us-gaap Valuation Allowances And Reserves Balance
ValuationAllowancesAndReservesBalance
1635000
CY2020Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
27705000
CY2019Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
22790000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
27705000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
22790000
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1884000
CY2019Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2098000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5665000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7704000
us-gaap Valuation Allowances And Reserves Charged To Cost And Expense
ValuationAllowancesAndReservesChargedToCostAndExpense
5956000
us-gaap Valuation Allowances And Reserves Deductions
ValuationAllowancesAndReservesDeductions
4230000
CY2019Q3 us-gaap Valuation Allowances And Reserves Balance
ValuationAllowancesAndReservesBalance
3361000
rigl Sales Discounts And Allowances
SalesDiscountsAndAllowances
10100000
CY2020Q3 us-gaap Valuation Allowances And Reserves Balance
ValuationAllowancesAndReservesBalance
4900000
rigl Contingent Payments Under Agreement
ContingentPaymentsUnderAgreement
607200000
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
13989943
CY2020Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
18389000
CY2019Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
20857000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
90171000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
43888000
CY2019Q4 us-gaap Valuation Allowances And Reserves Balance
ValuationAllowancesAndReservesBalance
3332000
us-gaap Valuation Allowances And Reserves Charged To Cost And Expense
ValuationAllowancesAndReservesChargedToCostAndExpense
9076000
us-gaap Valuation Allowances And Reserves Deductions
ValuationAllowancesAndReservesDeductions
7499000
CY2020Q3 us-gaap Valuation Allowances And Reserves Balance
ValuationAllowancesAndReservesBalance
4909000
CY2020Q3 us-gaap Inventory Net
InventoryNet
2050000
CY2019Q4 us-gaap Inventory Net
InventoryNet
1354000
CY2020Q3 us-gaap Advances On Inventory Purchases
AdvancesOnInventoryPurchases
4200000
CY2019Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
98078000
CY2020Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
36567000
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
22521000
CY2020Q3 us-gaap Short Term Investments
ShortTermInvestments
36245000
CY2019Q4 us-gaap Short Term Investments
ShortTermInvestments
75557000
CY2020Q3 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
72812000
CY2019Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
98078000
CY2020Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
53693000
CY2020Q3 us-gaap Inventory Work In Process
InventoryWorkInProcess
1043000
CY2019Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
810000
CY2020Q3 us-gaap Inventory Finished Goods
InventoryFinishedGoods
1007000
CY2019Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
544000
CY2020Q3 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
72812000
us-gaap Variable Lease Cost
VariableLeaseCost
704000
CY2020Q3 us-gaap Variable Lease Cost
VariableLeaseCost
237000
CY2020Q3 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
53695000
CY2019Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
87227000
CY2019Q4 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
87250000
rigl Cash Equivalents And Available For Sale Securities Weighted Average Maturity Period
CashEquivalentsAndAvailableForSaleSecuritiesWeightedAverageMaturityPeriod
P64D
CY2020Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
11
CY2020Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
14027000
CY2020Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
1000
rigl Lessee Leasing Arrangements Operating Leases Number Of Renewal Term Periods
LesseeLeasingArrangementsOperatingLeasesNumberOfRenewalTermPeriods
2
CY2020Q3 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P5Y
CY2020Q3 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P5Y
CY2014Q4 us-gaap Area Of Real Estate Property
AreaOfRealEstateProperty
57000
CY2017Q3 us-gaap Area Of Real Estate Property
AreaOfRealEstateProperty
9328
CY2020Q3 rigl Expected Income From Sublease
ExpectedIncomeFromSublease
10700000
CY2020Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
19900000
CY2020Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
21300000
CY2020Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y3M29D
CY2020Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
1340000
us-gaap Operating Lease Cost
OperatingLeaseCost
4020000
CY2020Q3 us-gaap Lease Cost
LeaseCost
1577000
us-gaap Lease Cost
LeaseCost
4724000
CY2020Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
2431000
us-gaap Operating Lease Payments
OperatingLeasePayments
7263000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
10082000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
10485000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
877000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
23875000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
2431000
CY2020Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
2612000
CY2020Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
21263000
CY2020Q3 rigl Fixed Sublease Expense
FixedSubleaseExpense
1096000
rigl Fixed Sublease Expense
FixedSubleaseExpense
3286000
CY2020Q3 rigl Variable Sublease Expense
VariableSubleaseExpense
245000
rigl Variable Sublease Expense
VariableSubleaseExpense
742000
CY2020Q3 us-gaap Sublease Income
SubleaseIncome
1341000
us-gaap Sublease Income
SubleaseIncome
4028000
CY2020Q3 rigl Sublease Payments To Be Received Remainder Of Fiscal Year
SubleasePaymentsToBeReceivedRemainderOfFiscalYear
1093000
CY2020Q3 rigl Sublease Payments To Be Received Two Years
SubleasePaymentsToBeReceivedTwoYears
4534000
CY2020Q3 rigl Sublease Payments To Be Received Three Years
SubleasePaymentsToBeReceivedThreeYears
4716000
CY2020Q3 rigl Sublease Payments To Be Received Four Years
SubleasePaymentsToBeReceivedFourYears
394000
CY2020Q3 rigl Sublease Payments To Be Received
SubleasePaymentsToBeReceived
10737000
CY2020Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
1667000
CY2020Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
6667000
CY2020Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
6667000
CY2020Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Five
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
4999000
CY2020Q3 us-gaap Long Term Debt
LongTermDebt
20000000

Files In Submission

Name View Source Status
0001558370-20-012838-index-headers.html Edgar Link pending
0001558370-20-012838-index.html Edgar Link pending
0001558370-20-012838.txt Edgar Link pending
0001558370-20-012838-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
rigl-20200930.xsd Edgar Link pending
rigl-20200930x10q.htm Edgar Link pending
rigl-20200930x10q004.jpg Edgar Link pending
rigl-20200930x10q_htm.xml Edgar Link completed
rigl-20200930xex10d1.htm Edgar Link pending
rigl-20200930xex31d1.htm Edgar Link pending
rigl-20200930xex31d2.htm Edgar Link pending
rigl-20200930xex32d1.htm Edgar Link pending
rigl-20200930_cal.xml Edgar Link unprocessable
rigl-20200930_def.xml Edgar Link unprocessable
rigl-20200930_lab.xml Edgar Link unprocessable
rigl-20200930_pre.xml Edgar Link unprocessable
Show.js Edgar Link pending